Cystic Fibrosis Foundation Therapeutics Announces $5 Million Award to Support Development of Anti-Inflammatory Treatment

Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), the nonprofit affiliate of the Cystic Fibrosis Foundation, announced today a $5 million development award to Corbus Pharmaceuticals for a potential new therapy to reduce lung inflammation in people with CF.

| 2 min read

The award will help fund a Phase 2 clinical trial of Resunab, a novel synthetic oral drug. Resunab has the potential to address inflammation in people with CF, regardless of an individual's CF gene mutations.

In people who have cystic fibrosis, lung inflammation is a chronic and life-threatening result of the disease, causing scarring and progressive lung damage.

Resunab is a potential treatment to reduce lung inflammation by stimulating the body's anti-inflammatory processes. Preclinical and Phase 1 clinical studies showed early promising results in reducing inflammation and scarring.

Corbus plans to begin the Phase 2 clinical trial for Resunab in the second quarter of 2015, pending U.S. Food and Drug Administration review of the proposed study.

“We're eager to help develop new therapies that manage the devastating effects of lung inflammation in people with CF,” said Robert J. Beall, Ph.D., president and CEO of the Cystic Fibrosis Foundation. “Our support reflects the Foundation's commitment to pursuing multiple research avenues to attack the disease from every angle.”

Corbus Pharmaceuticals is a biopharmaceutical company based in Norwood, Mass.

Read Corbus' press release.

Share this article
Topics
Research
Recent news
Teens Advocate for the PASTEUR Act as Part of the CF Foundation’s 14th Annual Teen Advocacy Day
News | 4 min read
CF Foundation Awards $1.6 Million to Improve Detection of Lung Transplant Complication
News | 5 min read
CF Foundation Announces New National Advocacy Chairs
News | 5 min read
Stay up to date with The Foundation

Sign up for our newsletter to get all of the latest news from The Foundation right in your inbox.

Subscribe